LGVN

Longeveron Inc. [LGVN] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

LGVN Stock Summary

Top 10 Correlated ETFs

LGVN

Top 10 Correlated Stocks

LGVN

In the News

LGVN Financial details

Company Rating
-
Market Cap
4.25M
Income
-22.14M
Revenue
709K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
23
Optionable
No
Shortable
Yes
Earnings
10 May 2024
P/E
-1.34
Forward P/E
-
PEG
-1.51
P/S
41.25
P/B
4.02
P/C
-
P/FCF
-1.77
Quick Ratio
1.19
Current Ratio
1.49
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-10.19
EPS next Y
-
EPS next Q
-
EPS this Y
5.24%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
44.38%
Revenue last 5Y
-33.95%
Revenue Q/Q
-58%
EPS Q/Q
-8.6%
-
-
-
-
SMA20
-9.2%
SMA50
-21.78%
SMA100
-21.39%
Inst Own
-
Inst Trans
-
ROA
-171%
ROE
-145%
ROC
-2.53%
Gross Margin
22%
Oper. Margin
-2716%
Profit Margin
-2593%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.62-44.0
52W High
-96.45%
52W Low
+56%
RSI
45.59
Rel Volume
0.11
Avg Volume
941.58K
Volume
101.58K
Perf Week
6.85%
Perf Month
-17.89%
Perf Quarter
-26.42%
Perf Half Y
-39.06%
-
-
-
-
Beta
0.196
-
-
Volatility
0.04%, 0.1%
Prev Close
-4.88%
Price
1.56
Change
-5.45%

Something similar

Top by Market Cap
AMZN
LLY
NVDA
0YXG.L
ABEC.DE
Top Correlated ETFs
HDRO
QCLN
PBW
FCG
HYDR
Top Correlated Stocks
DJCO
EXTR
FCEL
TNYA
WKHS
Similar Market Cap
VYCO
XXII
PCSA
VAO.DE
RIEH.TO

Company Profile

Healthcare Biotechnology
  • Volume Average 941.58K
  • Market Capitalization 4.25M
  • Employee 23
  • CEO Mr. Mohamed Wa'el Ahmed Hashad
  • Headquarters Miami,FL,US
  • IPO Date 2021-02-12
  • Website https://www.longeveron.com

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.